Key facts
- Fujifilm Holdings has invested 1 trillion yen ($6.31 billion) in its biomedical business.
- The company's bio-CDMO business focuses on contract manufacturing of biomedical products.
- Declining profitability is raising questions about the success of Fujifilm's biomedical venture.
Japanese technology group Fujifilm Holdings is facing questions regarding the success of its 1 trillion yen ($6.31 billion) investment in its biomedical business. The company's bio-CDMO (contract development and manufacturing organization) segment is involved in the contract manufacturing of biomedical products. However, declining profitability within this segment has led to doubts about whether the significant bet will ultimately pay off. The report, dated October 14, 2026, highlights the challenges Fujifilm is encountering in its transformation efforts within the biotechnology sector.